Galantamine for Alzheimer's disease and mild cognitive impairment.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2006-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD001747.PUB3PMID 16437436PMCID PMC8961200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change

  2017cited by this paper
• Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

  2005cited by this paper
• P4.015 Benefits of galantamine treatment in patients with ‘very mild’ Alzheimer's disease

  2004cited by this paper
• The Clinical Efficacy and Safety of Galantamine in the Treatment of Alzheimer's Disease

  2004cited by this paper
• Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease

  2004cited by this paper
• A 6‐month open‐label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease

  2004cited by this paper
• Correcting brain volumes for total intracranial volume: Applications in serial studies of Alzheimer's disease

  2004cited by this paper
• Long-term outcomes of galantamine treatment in patients with Alzheimer disease.

  2004cited by this paper
• P2-158 Effect of galantamine treatment on brain atrophy as assessed by MRI in patients with mild cognitive impairment

  2004cited by this paper
• Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.

  2004cited by this paper
• A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

  2004cited by this paper
• P4-007 Galantamine in the treatment of patients with mild cognitive impairment: effect of diagnostic type at baseline

  2004cited by this paper
• P1-324 Does galantamine therapy in mild to moderate Alzheimer's disease improve behaviour?

  2004cited by this paper
• Galantamine Maintains Ability to Perform Activities of Daily Living in Patients with Alzheimer's Disease

  2004cited by this paper
• Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans

  2004cited by this paper
• P1-367 Tolerability, safety and efficacy in patients with Alzheimer's disease who are switched from donepezil to galantamine

  2004cited by this paper
• Galantamine hydrobromide: an agent for Alzheimer's disease.

  2003cited by this paper
• Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine.

  2003cited by this paper
• GALANTAMINE: A REVIEW OF ITS USE IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA

  2003cited by this paper
• Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

  2003cited by this paper
• Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

  2003cited by this paper
• Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

  2003cited by this paper
• Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

  2003cited by this paper
• The effects of galantamine treatment on caregiver time in Alzheimer's disease

  2003cited by this paper
• Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

  2003cited by this paper
• Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease

  2003cited by this paper
• An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

  2003cited by this paper
• Galantamine in the Treatment of Vascular Dementia

  2003cited by this paper
• The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

  2003cited by this paper
• CLINICAL AND COST-EFFECTIVENESS OF DONEPEZIL, RIVASTIGMINE, AND GALANTAMINE FOR ALZHEIMER'S DISEASE

  2002cited by this paper
• Hypertensive encephalopathy: persistent MR‐abnormalities in a patient with good clinical recovery

  2002cited by this paper
• GALANTAMINE PROVIDES BROAD BENEFITS IN PATIENTS WITH ‘ADVANCED MODERATE’ ALZHEIMER'S DISEASE (MMSE ≤12) FOR UP TO SIX MONTHS

  2002cited by this paper
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  2002cited by this paper
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

  2002cited by this paper
• Cholinesterase inhibitors in dementia

  2002cited by this paper
• To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

  2002cited by this paper
• Non‐cognitive benefits of galantamine (Reminyl®) treatment in vascular dementia

  2002cited by this paper
• Use of galantamine to treat vascular dementia

  2002cited by this paper
• Galantamine in vascular dementia and Alzheimer’s disease combined with cerebrovascular disease

  2002cited by this paper
• Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial.

  2002cited by this paper
• Use of galantamine to treat vascular dementia.

  2002cited by this paper
• Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.

  2001cited by this paper
• Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

  2001cited by this paper
• Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

  2001cited by this paper
• Assessment of health economics in Alzheimer’s disease (AHEAD)

  2001cited by this paper
• Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

  2001cited by this paper
• Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

  2001cited by this paper
• Treatment of early Parkinson's disease

  2000cited by this paper
• Galantamine alleviates caregiver burden in Alzheimer's disease: A 6-month placebo-controlled study

  2000cited by this paper
• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Galantamine

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

  2000cited by this paper
• Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

  1999cited by this paper
• Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease

  1998cited by this paper
• Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

  1998cited by this paper
• Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists.

  1997cited by this paper
• An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease

  1997cited by this paper
• Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• Galanthamine in Alzheimer’s Disease

  1997cited by this paper
• CLINICAL STUDIES WITH GALANTHAMINE

  1997cited by this paper
• Pharmacokinetics and metabolism of galanthamine

  1997cited by this paper
• Preclinical studies with galanthamine

  1997cited by this paper
• Galanthamine

  1996cited by this paper
• Galanthamine

  1996cited by this paper
• Trial of a Selective Acetylcholinesterase Inhibitor, Galanthamine Hydrobromide, in the Treatment of Chronic Fatigue Syndrome

  1996cited by this paper
• Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.

  1995cited by this paper
• The pharmacology of galanthamine and its analogues.

  1995cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• Cholinergic neurotransmission, REM sleep and depression.

  1994cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Galanthamine in Alzheimer’s Disease

  1994cited by this paper
• Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep.

  1994cited by this paper
• Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition

  1991cited by this paper
• Galanthamine treatment in Alzheimer's disease.

  1991cited by this paper
• Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

  1990cited by this paper
• A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

  1988cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Bias in treatment assignment in controlled clinical trials.

  1983cited by this paper
• Interaction of reversible inhibitors with catalytic centers and allosteric sites of cholinesterases

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Dissecting specialized metabolism in space: A MALDI-MSI atlas of Amaryllidaceae alkaloids in Hippeastrum papilio (Ravenna) Van Scheepen.

  2026cites this paper
• A meta-analysis update evaluating the treatment effects of donepezil alone versus donepezil combined with memantine for Alzheimer's disease

  2025cites this paper
• Targeting together cholinesterases and serotonin reuptake against Alzheimer's disease.

  2025cites this paper
• Alkaloids as neuroprotectors: targeting signaling pathways in neurodegenerative diseases

  2025cites this paper
• Pathological mechanisms and treatment progression of Alzheimer’s disease

  2025cites this paper
• Rapid health technology assessment of galantamine for the treatment of Alzheimer’s disease: A review

  2025cites this paper
• Polymers for the treatment of Alzheimer’s disease

  2025cites this paper
• Coclaurine N-methyltransferase-like enzymes drive the final biosynthetic reaction of the anti-Alzheimer's drug galanthamine in Amaryllidaceae.

  2025cites this paper
• A vagal route to memory: evidence from invasive and non-invasive electrical vagus nerve stimulation studies and areas for future clinical application

  2025cites this paper
• Immunotherapies: A Treasure Trove of Alzheimer's Disease.

  2024cites this paper
• Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA‐DEM cohort

  2024cites this paper
• Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study

  2024cites this paper
• Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

  2024cites this paper
• A Comprehensive Review of Therapeutic Compounds from Plants for Neurodegenerative Diseases.

  2024cites this paper
• Non-competitive inhibition of acetylcholinesterase by jaboticaba (Myrciaria cauliflora) peel ethanolic extracts

  2024cites this paper
• Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives

  2024cites this paper
• Alzheimer's Disease Protein Targets: Comprehensive Review and Future Directions.

  2024cites this paper
• The neuropharmacological and clinical effects of lutein: a systematic review

  2024cites this paper
• [Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study].

  2024cites this paper
• Accuracy of Labeling of Galantamine Generic Drugs and Dietary Supplements.

  2024cites this paper
• Navigating Amaryllidaceae alkaloids: bridging gaps and charting biosynthetic territories

  2024cites this paper
• Linking altered neuronal and synaptic properties to nicotinic receptor Alpha5 subunit gene dysfunction: a translational investigation in rat mPFC and human cortical layer 6

  2024cites this paper
• Current understanding and future directions of cruciferous vegetables and their phytochemicals to combat neurological diseases

  2024cites this paper
• Effectiveness of Novel Drug Delivery System using Curcumin in Alzheimer's Disease.

  2024cites this paper
• Repurposing non-pharmacological interventions for Alzheimer's disease through link prediction on biomedical literature

  2024cites this paper
• Drug repurposing for neurodegenerative diseases.

  2024cites this paper
• Acetylcholine and metacognition during sleep.

  2023cites this paper
• Repurposing Non-pharmacological Interventions for Alzheimer's Diseases through Link Prediction on Biomedical Literature

  2023cites this paper
• Repurposing of clinically proven bioactive compounds for targeted treatment of Alzheimer’s disease using molecular docking approach

  2023cites this paper
• Significance of Astragaloside IV from the Roots of Astragalus mongholicus as an Acetylcholinesterase Inhibitor—From the Computational and Biomimetic Analyses to the In Vitro and In Vivo Studies of Safety

  2023cites this paper
• What would a population‐level approach to dementia risk reduction look like, and how would it work?

  2023cites this paper
• Transnasal-brain delivery of nanomedicines for neurodegenerative diseases

  2023cites this paper
• Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions

  2023influential citation
• Aducanumab: A new hope in Alzheimer's Disease

  2022cites this paper
• Alkaloids with cholinesterase inhibitory activities from the bulbs of Crinum × amabile Donn ex Ker Gawl.

  2022cites this paper
• Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges

  2022cites this paper
• WBI Studies Repository WBI Studies Clinical trials and late-stage drug development in Alzheimer’s Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014 disease: An appraisal from 1984 to 2014

  2022cites this paper
• Harnessing plant biotechnology-based strategies for in vitro galanthamine (GAL) biosynthesis: a potent drug against Alzheimer’s disease

  2022cites this paper
• In Silico and In Vitro Studies of Benzothiazole-Isothioureas Derivatives as a Multitarget Compound for Alzheimer’s Disease

  2022cites this paper
• Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias.

  2022cites this paper
• Effect of a multimodal non-pharmacological intervention on older people with dementia: a single-case experimental design study

  2022cites this paper
• Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer’s Disease

  2022cites this paper
• The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial.

  2021cites this paper
• Bis (Diamines) Cu and Zn Complexes of Flurbiprofen as Potential Cholinesterase Inhibitors: In Vitro Studies and Docking Simulations

  2021cites this paper
• Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial

  2021cites this paper
• Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021

  2021cites this paper
• Galantamine

  2021cites this paper
• Anti-dementia Medication

  2021cites this paper
• Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review

  2021cites this paper
• European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment

  2021cites this paper
• Safety and efficacy of dietary supplement (gintonin-enriched fraction from ginseng) in subjective memory impairment: A randomized placebo-controlled trial

  2021cites this paper
• Diagnosis and Treatment of Alzheimer’s Disease:

  2021cites this paper
• Tau fibril with membrane lipids: Insight from computational modeling and simulations

  2021cites this paper
• Sex differences in psychiatric disorders and their implication for dementia

  2021cites this paper
• Drugs for Treatment of Cognitive Disorders

  2020cites this paper
• Effect of desalted Salicornia europaea L. ethanol extract (PM-EE) on the subjects complaining memory dysfunction without dementia: a 12 week, randomized, double-blind, placebo-controlled clinical trial

  2020cites this paper
• Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.

  2020cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine

  2020cites this paper
• Evaluation of the Therapeutic Effect of Lycoramine on Alzheimer's Disease in Mouse Model.

  2020cites this paper
• Bayesian analysis of the association between effective strategies of multimodal nonpharmacological intervention and characteristics of cognitive function in nursing home residents with cognitive impairment

  2020cites this paper
• Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease.

  2020cites this paper
• A Perspective on Multi-target Drugs for Alzheimer's Disease.

  2020cites this paper
• Natural Medicines and Their Underlying Mechanisms of Prevention and Recovery from Amyloid Β-Induced Axonal Degeneration in Alzheimer’s Disease

  2020cites this paper
• Functional Evolving Patterns of Cortical Networks in Progression of Alzheimer's Disease: A Graph-Based Resting-State fMRI Study

  2020cites this paper
• Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study

  2019cites this paper
• University of Dundee Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older ?

  2019cites this paper
• Psychopharmacology and pharmacokinetics.

  2019cites this paper
• Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older?

  2019cites this paper
• Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer''s disease.

  2019cites this paper
• The Effects of the Digital Platform Support Monitoring and Reminder Technology for Mild Dementia (SMART4MD) for People With Mild Cognitive Impairment and Their Informal Carers: Protocol for a Pilot Randomized Controlled Trial

  2019cites this paper
• Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities

  2019cites this paper
• Insights into Computational Drug Repurposing for Neurodegenerative Disease.

  2019cites this paper
• Pristup liječenju Alzheimerove bolesti / Treatment Approach to Alzheimer’s Disease

  2019cites this paper
• Безопасность применения ингибиторов холинэстеразы и антагонистов NMDA-рецепторов для лечения пациентов с деменцией

  2019cites this paper
• France removes state funding for dementia drugs

  2019cites this paper
• Management of Alzheimer's disease

  2019cites this paper
• Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

  2019cites this paper
• Cognitive symptoms of Alzheimer’s disease: clinical management and prevention

  2019cites this paper
• Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis

  2019cites this paper
• Comparison of cholinesterase inhibitor safety in real-world practice

  2019cites this paper
• Effects of traditional Chinese exercise on cognitive and psychological outcomes in older adults with mild cognitive impairment

  2019cites this paper
• Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia

  2018cites this paper
• Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

  2018cites this paper
• Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs

  2018cites this paper
• Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease

  2018cites this paper
• World Alzheimer Report 2011 : The benefits of early diagnosis and intervention

  2018cites this paper
• Brazilian Green Propolis Prevents Cognitive Decline into Mild Cognitive Impairment in Elderly People Living at High Altitude

  2018cites this paper
• Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis

  2018cites this paper
• Effect of the replacement of dietary vegetable oils with a low dose of extravirgin olive oil in the Mediterranean Diet on cognitive functions in the elderly

  2018cites this paper
• Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease

  2018cites this paper
• The Black Book of Psychotropic Dosing and Monitoring.

  2018cites this paper
• Cholinergic medication for antipsychotic-induced tardive dyskinesia

  2018cites this paper
• Memantine improves semantic memory in patients with amnestic mild cognitive impairment: A single-photon emission computed tomography study

  2017cites this paper
• Impact of legumes and plant proteins consumption on cognitive performances in the elderly

  2017cites this paper
• Emerging amyloid and tau targeting treatments for Alzheimer’s disease

  2017cites this paper
• Medikamentöse Alternativen zu Antipsychotika bei Verhaltensstörungen

  2017cites this paper
• Herbal medicine for management of the behavioural and psychological symptoms of dementia (BPSD): A systematic review and meta-analysis

  2017cites this paper
• Nanotechnology‐based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

  2017cites this paper
• Geriatric Disorders: Evidence-Based Integrated Biopsychosocial Treatment of Depression, Dementia, and Dementia-Related Disorders in the Elderly

  2017cites this paper
• Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

  2017cites this paper